Due to regulatory compliance, trying to implement an OpenSource solution into clinical practice is inherently difficult. The medical sector needs rigorous rules to keep patients as far away from unecessary risk as possible.
Oncoradiomics clinical grade solutions are currently CE marked and therefore respect the rules and regulations imposed by the European Union. They are ready to be implemented in Europe without you having to go through any regulatory compliance yourself.
Oncradiomics solutions will be FDA approved by the end of 2019, making them ready to be implemeted in the United States with zero hassle on your end.